TICKERNERD
Menu
DCGODCGOHealthcare · Medical Care Facilities

DCGO Stock Forecast: DocGo, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$0.40
−0.49% on the day

The 5 Wall Street analysts covering DocGo, Inc. hold a median 12-month price target of $1.75 — +334.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$39.9M
Ticker Nerd rank
36 / 100
Median analyst target
$1.75
Analysts covering
5
Revenue$73.4M−8.7% y/y
Operating income−$17.9M
Net income−$18.0M
Free cash flow−$10.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.3%
1M
−38.2%
YTD
−54.1%
1Y
−73.3%
From 52W high
−74.5%
From 52W low
+5.8%
$0.38
$1.58
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DCGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DocGo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Issuance
95
Size
84
Revisions
28
Growth
27
Volatility
24
Value
22
Quality
21
Momentum
14

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DCGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26DCGOHigh $3.00Median $1.75Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
2 Buy3 Hold0 Sell
Low $1.00Median $1.75High $3.00

The green dot is the last close — the median target sits +334.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Canaccord GenuityMaintainsHold$1.00
18 Aug 2026NeedhamReiteratesBuy$3.00
25 Mar 2026Canaccord GenuityMaintainsHold$1.50 → $1.00
25 Mar 2026Canaccord GenuityMaintainsHold—
17 Mar 2026Cantor FitzgeraldReiteratesOverweight—
17 Mar 2026NeedhamReiteratesBuy—
17 Mar 2026StifelMaintainsBuy—
12 Nov 2025Canaccord GenuityMaintainsHold—
21 Aug 2025Canaccord GenuityMaintainsHold—
12 May 2025Canaccord GenuityDowngradeHold—
9 May 2025NeedhamMaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—
28 Feb 2025NeedhamMaintainsBuy—
28 Feb 2025StifelMaintainsBuy—
16 Jan 2025NeedhamReiteratesBuy—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight—
20 Aug 2024Cantor FitzgeraldReiteratesOverweight—
8 Aug 2024NeedhamReiteratesBuy—
9 May 2024BTIGMaintainsBuy—
9 May 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCGO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DCGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, DocGo, Inc. returned −73.3% against +20.0% for the S&P 500, dividends included.

DCGO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26DCGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DCGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

DocGo, Inc. (DCGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
8.5×

Cheaper than 61% of US stocks

Price / sales
0.1×

Cheaper than 95% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−8.7%

Higher than 17% of US stocks

Earnings growth (YoY)
−8.7%

Higher than 27% of US stocks

Gross margin
30.5%

Higher than 35% of US stocks

Operating margin
−24.4%

Higher than 21% of US stocks

Net margin
−65.3%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−107.8%

Higher than 12% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DocGo, Inc. (DCGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DocGo, Inc. has a market value of $39.9M and an enterprise value of $17.2M.

  • Revenue in the twelve months to 30 June 2026: $294.7M. The latest quarter shrank 8.7% year on year.

  • Net income over the same four quarters: −$206.7M, a −70.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.96.

  • Free cash flow in the twelve months to 30 June 2026: −$28.6M.

  • DocGo, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 98.9M.

  • Trailing P/E: 8.5×; forward P/E: 10.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • DocGo, Inc. employs 2,537 people — $116K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

DCGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
DCGODocGo, Inc.$39.9M
36
CCELCryo-Cell International, Inc.$34.5M
74
BTMDbiote Corp.$54.9M
71
PIIIP3 Health Partners, Inc.$67.9M
67
PARKPark Dental Partners, Inc.$97.2M
13
JYNTThe Joint Corp. (United States)$117.4M
89
AMSAmerican Shared Hospital Services$9.5M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DocGo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DCGO news & analysis

DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference

Business Wire · 1 Sept 2026neutral

DocGo announced that CEO Lee Bienstock will participate in one-on-one meetings and deliver a fireside presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th. A webcast of the event will be made available on the investor relations section of DocGo's website.

Why it matters — A DCGO watcher would care because the CEO's presentation at a major healthcare investment conference offers investors an opportunity to hear directly from management about the company.

DocGo Q2 Earnings Call Highlights

MarketBeat · 17 Aug 2026neutral

DocGo reported second-quarter revenue of $73.4 million, down from $80.4 million a year earlier, as it continued to wind down migrant-related projects. Excluding that revenue, overall revenue rose 19% year over year, and revenue from business lines operating in both periods grew about 5% after also excluding SteadyMD contributions.

Why it matters — A DocGo watcher would care because the report shows how the company's underlying growth looks once the wind-down of migrant-related projects is removed, offering a clearer view of its base business performance.

DocGo Inc. (DCGO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 17 Aug 2026neutral

DocGo Inc. held its Q2 2026 earnings call, with a transcript of the event published by Seeking Alpha. The call covered the company's second-quarter financial results and related discussion.

Why it matters — The earnings call transcript provides DCGO watchers with direct insight into the company's latest quarterly performance and management commentary.

DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates

Zacks Investment Research · 17 Aug 2026positive

DocGo Inc. reported Q2 earnings of $0.16 per share, beating the Zacks Consensus Estimate of a $0.04 per-share loss. This compares to a loss of $0.11 per share in the same period a year ago.

Why it matters — The result shows DocGo exceeded analyst expectations and swung from a year-ago loss to a profit, an important development for those tracking the company's performance.

DocGo Announces Second Quarter 2026 Results

Business Wire · 17 Aug 2026negative

DocGo announced its financial and operating results for the second quarter ended June 30, 2026. Total revenue was $73.4 million, down from $80.4 million in the same quarter of 2025, a decline the company attributed entirely to the wind-down of migrant-related programs.

Why it matters — The revenue decline tied to the wind-down of migrant-related programs is a key factor for DCGO watchers assessing the company's current performance and revenue trajectory.

FAQ

Frequently asked questions about DCGO stock

What is the DCGO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering DocGo, Inc. have a median 12-month price target of $1.75, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCGO stock a buy right now?

Of the 5 analysts covering DocGo, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DocGo, Inc. 36 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCGO?

As at 5 Sept 2026, DocGo, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will DCGO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +334.3% from the last close, and Ticker Nerd's factor model ranks DocGo, Inc. 36 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCGO stock forecast for 2030?

No analyst covering DocGo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.

How has DCGO stock performed over the past year?

DocGo, Inc. returned -73.3% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DocGo, Inc. do?

DocGo Inc. is a healthcare services company that provides mobile health and medical transportation solutions for patients, hospitals, health systems, insurers, employers, and public-sector organizations.

What is the latest news on DCGO?

The most recent item we track (Business Wire, 1 Sept 2026): "DocGo Announces Upcoming Participation at Morgan Stanley 24th Annual Global Healthcare Conference". DocGo announced that CEO Lee Bienstock will participate in one-on-one meetings and deliver a fireside presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th. A webcast of the event will be made available on the investor relations section of DocGo's website.

Company

About DocGo, Inc.

DocGo Inc. is a healthcare services company that provides mobile health and medical transportation solutions for patients, hospitals, health systems, insurers, employers, and public-sector organizations. DocGo Inc. combines proprietary technology with skilled clinicians to deliver care through mobile and virtual channels, including in-home and on-site urgent care, diagnostic testing, vaccinations, monitoring, care management, and remote patient support. Its transportation services include emergency response and non-emergency medical transport such as ambulance and wheelchair services. The company also supports event-based healthcare coverage and mobile clinical programs designed to extend care beyond traditional facilities. Headquartered in New York, DocGo Inc. plays a role in the shift toward more accessible, decentralized care delivery across the United States and the United Kingdom.

CEO Mr. Lee Bienstock · 2,537 employees · United States · https://docgo.com